Home About Us Industry Report Store Resources Contact us

Tumor Treating Fields Market To Reach USD 1236.84 Million By Year 2032

The Global Tumor Treating Fields Market Size Was Valued at USD 332.9 Million in 2023 and is Projected to Reach USD 1236.84 Million by 2032, Growing at a CAGR of 15.7 % from 2024-2032.

shashidhar kotian
Pristine Intelligence LLP

According to a new report published by Pristine Market Research, titled, “Tumor Treating Fields Market by Product Type, Indication, Frequency, End User, and Region Global Market Analysis and Forecast, 2024-2032. The Global Tumor Treating Fields Market Size Was Valued at USD 332.9 Million in 2023 and is Projected to Reach USD 1236.84 Million by 2032, Growing at a CAGR of 15.7 % from 2024-2032.

Tumor Treating Fields (TTFields) are electric fields that disrupt cellular processes critical for cancer cell survival and tumor growth without affecting healthy cells. These fields are administered to tumors using arrays placed on the patient's skin, allowing for non-invasive treatment without invasive procedures. The frequency of TTFields falls between 100 kHz and 500 kHz, making it suitable for tissue stimulation and heating. The most effective frequency is 150 kHz for NSCLC and pancreatic cancer cells and 200 kHz for ovarian cancer cells. The NovoTTF-200 is a portable medical tool used for TTFields treatment, which is recommended for a minimum of 18 hours per day. The device has been restructured and updated to improve patient acceptance and usage. The market for TTFields is expanding due to increasing healthcare provider usage and regulatory clearances.

According to the Tumor Treating Fields, the Market is segmented into Product Type, Indication, Frequency, and End User. By Product, the market is categorized into Transducer Arrays, Tumor Treating Field Generators, and Others. By Indication, the market is categorized into Glioblastoma Multiforme, Non-small Cell Lung Cancer, Pancreatic Cancer, Ovarian Cancer, Mesothelioma, Brain Metastasis, and Others. By Frequency, the market is categorized into Low Frequency and intermediate Frequency. By End User, the market is categorized into Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Others. By region, it is analyzed across North America (U.S.; Canada; Mexico), Europe (Germany; U.K.; France; Italy; Russia; Spain, etc.), Asia-Pacific (China; India; Japan; Southeast Asia, etc.), South America (Brazil; Argentina, etc.), Middle East & Africa (Saudi Arabia; South Africa, etc.).

TTFields is a promising non-invasive treatment for glioblastoma, the most aggressive form of brain cancer. It uses low-intensity, intermediate-frequency alternating electrical fields applied via cutaneous transducer arrays to influence charged molecules and inhibit cancer cell growth. This method has increased the lifespan of patients with newly diagnosed and recurrent GBM and mesothelioma, resulting in FDA recognition. Clinical trials are investigating its potential for treating solid tumors like mesothelioma, lung cancer, and pancreatic cancer. The TTFields market represents a new frontier in cancer therapies, preventing tumor growth while reducing harmful effects on healthy tissues

The market for Tumor Treating Fields (TTFields) is expected to grow due to the increasing incidence of cancer worldwide, particularly in brain cancer. TTFields therapy uses changing electric fields to interrupt cancer cell division, providing a non-invasive option for patients. Despite being expensive, TTField devices offer better patient outcomes and fewer side effects. The market is expected to be led by North America due to strong awareness and investments in research. The Asia Pacific region is also expected to see rapid growth, supported by a growing patient population and better access to advanced cancer treatments in developing countries. Opportunities for market expansion include launching new products and improving device design.

Global Tumor Treating Fields Market, Segmentation

Aluminum Extrusion Market is Segmented Based on Product Type, Indication, Frequency, End User, and Region.

By Product:

The Transducer Arrays Segment Is Expected to Dominate the Market During the Forecast Period. The transducer array sector dominates the Tumor Treating Fields (TTFields) market, playing a crucial role in effective tumor management. These arrays, widely used in medical settings, use electromagnetic fields to interfere with cancer cell division, providing a non-intrusive treatment option. The market favors transducer arrays for their accurate, focused treatment, hygienic, and efficient treatment sessions. The segment's growth is largely due to its widespread use in managing various cancers. As research and development progress, transducer arrays are expected to continue to be essential in cancer treatment.

By Indication:

The Glioblastoma Multiforme Segment Held the Largest Share. Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor in adults, with minimal survival advantages. Current treatments include surgery, radiation therapy, and chemotherapy with temozolomide, but the average survival time is 10-16 months. TTFields therapy, a non-invasive method using low-intensity, intermediate-frequency electric fields, has shown promise in treating GBM by inhibiting cancer cell growth and impacting biological activities like DNA repair and cell permeability. Clinical trials have confirmed its benefits, leading to FDA approval and ongoing research in various cancer types.


North America is expected to dominate the Tumor Treating Fields (TTFields) market, holding over 42.9% of the market share in I2023. This leadership is due to the high cancer cases in the region, which demand advanced treatments like TTFields. The region also has a strong healthcare system, with healthcare providers and patients well-informed about TTFields therapy. This understanding facilitates early uptake and incorporation of TTFields into medical settings, strengthening market expansion. North America's strong healthcare system and well-informed healthcare system contribute to its leadership role in driving progress in cancer treatment technologies and establishing a strong presence in the global TTFields market.

Some of The Leading/Active Market Players Are-

  • Boston Scientific Corporation (U.S.)
  • Varian Medical Systems, Inc. (U.S.)
  • Johnson & Johnson (U.S.)
  • GE Healthcare (U.S.)
  • Accuray Incorporated (U.S.)
  • Stryker Corporation (U.S.)
  • Zimmer Biomet Holdings, Inc. (U.S.)
  • Roche (U.S.)
  • Pfizer Inc. (U.S.)
  • Merck & Co., Inc. (U.S.) and Other Active Players

Key Industry Developments

In January 2024, Varian, a company owned by Siemens Healthineers, and Nova Scotia Health have revealed an innovative 10-year, CAD 175 million multi-disciplinary oncology partnership (MDOP). This partnership seeks to enhance cancer treatment throughout Nova Scotia by simplifying the patient experience from diagnosis to recovery. The collaboration aims to improve cancer workflows and precision treatments in Nova Scotia, where cancer rates are higher than average among its 1 million inhabitants. By utilizing Siemens Healthineers' knowledge, the effort highlights a dedication to enhancing healthcare through innovation and enhancing survival rates in the area. 

In June 2024, Boston Scientific Corporation confirmed a definitive deal to acquire Silk Road Medical, Inc., a top provider of medical equipment for avoiding strokes in individuals with carotid artery issues. Silk Road Medical's unique platform is centered on TCAR, a minimally invasive procedure for revascularizing the carotid artery. The purchase, worth around $1.16 billion at $27.50 per share, highlights Boston Scientific's dedication to improving its cardiovascular offerings and enhancing its abilities to address important medical concerns regarding stroke prevention.

Key Findings of the Study:

  • The transducer array segment is expected to dominate the market due to its widespread use in managing various cancers with accurate and focused treatment capabilities.
  • Glioblastoma multiforme (GBM) holds the largest market share among indications, benefiting significantly from TTFields therapy's non-invasive approach.
  • North America leads the market share, driven by high cancer incidence, advanced healthcare systems, and early adoption of TTFields therapy.
Pristine Intelligence LLP

Conatct Us

Would you like to get in touch? We'll be happy to talk!

Press Contact